Pharmaceutical Market Europe • April 2026 • 3
COMMENT
In our cover story this month, Danny Buckland looks at weight loss medication and how GLP-1s have been shown to provide game-changing opportunities for patients who are overweight or obese to improve their health.
In a sector projected to reach an annual value of $150bn by 2035, the race is on to launch GLP-1 weight loss pills to help give patients better ease of use than the currently available GLP-1 weight loss injections.
However, while scientific advances have enabled the creation of weight loss medications that work by suppressing patients’ appetites, it is vital that their use is combined with a deep understanding of the complex psychological and societal triggers that underpin obesity and defy behaviour change. Read more on page 28.
Another highlight of this issue is an article on the continued search for a cure for tuberculosis, which remains one of the most persistent infectious diseases in human history. It is difficult to cure and treatment requires an extended period of time – currently, at least six months – to completely eliminate the hardy infection. Antibiotic courses must be completed but, for TB, the prolonged length of treatment and the side effects of drugs often hinder treatment adherence. Find out more on page 16.
In this issue we also have an article on the challenges of finding a cure for lupus and related autoimmune conditions. Of those with lupus, 90% are women who are most often diagnosed between the ages of 15 and 45, and black, Latinx, Indigenous, Asian and Pacific Islander people are disproportionately affected.
The development of new therapies and diagnostics for autoimmune diseases is an area of high unmet need that has long been overlooked. Now cell therapies, like CAR-T, which have transformed cancer treatment, are being investigated for autoimmune disease such as lupus. Turn to page 18 for more.
Our June issue will look at achieving launch excellence through strong cross-functional collaboration, real-time insights and engaging with diverse stakeholders from the start. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2026 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW